The estimated Net Worth of David M Stack is at least $23.3 Million dollars as of 6 June 2023. Mr. Stack owns over 10,384 units of Pacira BioSciences Inc stock worth over $1,999,153 and over the last 21 years he sold PCRX stock worth over $15,446,630. In addition, he makes $5,806,430 as Chairman of the Board and Chief Executive Officer at Pacira BioSciences Inc.
David has made over 73 trades of the Pacira BioSciences Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 10,384 units of PCRX stock worth $398,849 on 6 June 2023.
The largest trade he's ever made was exercising 90,000 units of Pacira BioSciences Inc stock on 14 October 2020 worth over $972,900. On average, David trades about 15,431 units every 75 days since 2003. As of 6 June 2023 he still owns at least 153,781 units of Pacira BioSciences Inc stock.
You can see the complete history of Mr. Stack stock trades at the bottom of the page.
David M. Stack serves as Chairman of the Board, Chief Executive Officer of the Company. Mr. Stack was appointed as the Chairman of our board of directors. Mr. Stack was Managing Director of MPM Capital, a private equity firm, from 2005 through March 2017 and has been a Managing Partner of Stack Pharmaceuticals, Inc., a commercialization, marketing, and strategy firm, since 1998. From 2001 to 2004, he was President and Chief Executive Officer of The Medicines Company (Nasdaq: MDCO). Previously, Mr. Stack was President and General Manager at Innovex, Inc. He was Vice President, Business Development/Marketing at Immunomedics from 1993 until 1995. Prior to that, he was with Roche Laboratories in positions of increasing responsibility from 1981 until 1993, including Therapeutic World Leader in Infectious Disease and Director, Business Development and Planning, Infectious Disease, Oncology, and Virology. He currently serves as a member of the board of directors of Prognos AI and Amarin Corporation plc (Nasdaq: AMRN). He also currently serves as Chairman of Chiasma, Inc. and is on the board of directors of the Biotechnology Industry Organization's (BIO) Emerging Company and Health Sections. He was a member of the boards of directors of Molecular Insight Pharmaceuticals, Inc. (Nasdaq: MIPI) from 2006 to 2010 and BioClinica, Inc. (Nasdaq: BIOC) from 1999 to 2010. Mr. Stack holds a B.S. in pharmacy from Albany College of Pharmacy and a B.S. in Biology from Siena College.
As the Chairman of the Board and Chief Executive Officer of Pacira BioSciences Inc, the total compensation of David Stack at Pacira BioSciences Inc is $5,806,430. There are no executives at Pacira BioSciences Inc getting paid more.
David Stack is 69, he's been the Chairman of the Board and Chief Executive Officer of Pacira BioSciences Inc since 2015. There are 2 older and 23 younger executives at Pacira BioSciences Inc. The oldest executive at Pacira BioSciences Inc is Gary Pace, 72, who is the Independent Director.
David's mailing address filed with the SEC is C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA, FL, 33609.
Over the last 14 years, insiders at Pacira BioSciences Inc have traded over $321,391,130 worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth $15,133,188 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon, and Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of $491,036. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth $20,034.
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
Pacira BioSciences Inc executives and other stock owners filed with the SEC include: